Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Reliable and valid assessment of procedural skills in resuscitative endovascular balloon occlusion of the aorta (REBOA)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • X Long Zheng
  • Sara K Vesely
  • Spero R Cataland
  • Paul Coppo
  • Brian Geldziler
  • Alfonso Iorio
  • Masanori Matsumoto
  • Reem A Mustafa
  • Menaka Pai
  • Gail Rock
  • Lene Russell
  • Rawan Tarawneh
  • Julie Valdes
  • Flora Peyvandi
Vis graf over relationer

BACKGROUND: Despite an increase in our understandings of pathogenesis of thrombotic thrombocytopenic purpura (TTP), the approaches for initial diagnosis and management of TTP vary significantly.

OBJECTIVE: The evidence-based guidelines of the International Society on Thrombosis and Haemostasis (ISTH) are intended to support patients, clinicians, and other health care professionals in their decisions about the initial diagnosis and management of acute TTP.

METHODS: In June 2018, ISTH formed a multidisciplinary panel that included hematologists, an intensive care physician, nephrologist, clinical pathologist, biostatistician, and patient representatives, as well as a methodology team from McMaster University. The panel composition was designed to minimize the potential conflicts of interests. The panel used the Grading of Recommendations Assessment, Development, and Evaluation approach and the Population, Intervention, Comparison, Outcome framework to develop and grade their recommendations. Public comments were sought and incorporated in the final document.

RESULTS: The panel agreed on three recommendations covering the initial diagnosis with emphasis on the importance of ADAMTS13 testing (eg, activity, anti-ADAMTS13 IgG or inhibitor) and assessment of the pretest probability of TTP by clinical assessment and/or the risk assessment models like the PLASMIC or French score. The panel noted how availability and turnaround time of ADAMTS13 test results might affect early diagnosis and management, in particular the use of caplacizumab.

CONCLUSIONS: There is a lack of high-quality evidence to support strong recommendations for the initial diagnosis and management of a suspected TTP. The panel emphasized the importance of obtaining ADAMTS13 testing in a proper clinical context. Future research should focus on how to monitor and act on ADAMTS13 levels during remission.

OriginalsprogEngelsk
TidsskriftJournal of thrombosis and haemostasis : JTH
Vol/bind18
Udgave nummer10
Sider (fra-til)2486-2495
Antal sider10
ISSN1538-7933
DOI
StatusUdgivet - okt. 2020

Bibliografisk note

© 2020 International Society on Thrombosis and Haemostasis.

ID: 61230892